LIVINGSTON, N.J., April 15 /PRNewswire-FirstCall/ -- MM2 Group, Inc. (OTC Bulletin Board: MMGP) announced today that its wholly-owned subsidiary, Genotec Nutritionals, Inc., a New York based nutraceutical company which generates its sales from the distribution of its branded products and through custom formulations for several large strategic partners, has closed on a sale for the manufacture of fish oil sofgels. The sofgels will be manufactured in China at the plant of Genotec's joint venture partner.
The customer is one of the largest companies in the nutraceutical industry. While the transaction is initially valued at roughly $170,000, it is anticipated that this order can become a monthly or bi-monthly order, depending upon the customer's satisfaction with the initial shipment.
The current capacity of the state of the art plant is 1.5 billion capsules per year. The plant was designed and built according to the latest cGMP requirements, in full compliance with both U. S. and China standards. The plant is capable of expanding capacity to 5 billion sofgel capsules per year.
George Kontonotas, President of Genotec, stated, "We are very excited about this venture. The plant is a China SFDA certified facility that complies with cGMP manufacturing standards. These high standards, which allow the plant to currently manufacture pharmaceuticals, make this among the highest quality plants which can be found manufacturing products in the nutritional supplement marketplace."
Mark Meller, CEO of MM2 Group, commented, "This is just the first step in our plan. Following the completion of this order, we will have one of the largest and most prestigious companies in the industry as a reference-able customer. As a result, we expect that other, smaller companies will jump in line to take advantage of our cost competitive and high quality products. We hope to be in a position to make several exciting announcements in the near future regarding sales activity from this new venture."
About MM2 Group, Inc.
MM2 Group is involved in the acquisition and build-out of dietary supplement and nutraceutical companies. The company's growth strategy is to acquire firms in this extensive and expanding but highly fragmented segment as it seeks to create substantial value for shareholders. For more information, contact MM2 Group CEO Mark Meller at (732) 290-0019 or by e-mail at [email protected] or Jerry Mahoney at [email protected].
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, regarding among other things our plans, strategies and prospects -- both business and financial. Although we believe that our plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, we cannot assure you that we will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Many of the forward-looking statements contained in this news release may be identified by the use of forward-looking words such as "believe," "expect," "anticipate," "should," "planned," "will," "may," "intend," "estimated," and "potential," among others. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include market conditions and those set forth in reports or documents that we file from time to time with the United States Securities and Exchange Commission. All forward-looking statements attributable to MM2 Group, Inc. or a person acting on its behalf are expressly qualified in their entirety by this cautionary language.
SOURCE MM2 Group, Inc.
